Macrophage News and Research

RSS

A macrophage is a type of white blood cell that surrounds and kills microorganisms, removes dead cells, and stimulates the action of other immune system cells.

New research shows cellular changes in fat tissue lead to type 2 diabetes

Cellular changes in fat tissue-not the immune system-lead to the "hyperinflammation" characteristic of obesity-related glucose intolerance and type 2 diabetes, according to new research from the University of Cincinnati.

7 Jul 2010

Multicolor quantum dots can distinguish Reed-Sternberg cells, article shows

The tunable fluorescent nanoparticles known as quantum dots make ideal tools for distinguishing and identifying rare cancer cells in tissue biopsies, Emory and Georgia Tech scientists have demonstrated.

7 Jul 2010

Scientist at Children Hospital Los Angeles receives NIH grant to research on meningitis

A white blood cell that normally removes bacteria from the bloodstream helps Escherichia coli (E. coli) accumulate in the blood and enter the brain resulting in the deadly infection known as meningitis. Prasadarao V. Nemani, PhD, a scientist at The Saban Research Institute at Children Hospital Los Angeles plans to find out how this happens with a grant of $1.65 million from the National Institutes of Health - National Institute of Neurological Disorders and Strokes.

25 Jun 2010

START proteins could help treat cholesterol build-up in arteries: Report

A newly discovered group of proteins could help treat cholesterol build-up in arteries. This build-up leads to atherosclerosis or 'hardening of the arteries', and the resulting condition, coronary heart disease, kills an estimated 124,000 each year in England and Wales.

23 Jun 2010

Expression of BCRP in RA patients may indicate higher disease activity, predict resistance to DMARDs

The expression of a transporter protein called the Breast Cancer Resistance Protein in rheumatoid arthritis patients may indicate higher disease activity and could be a barrier to the effectiveness of disease-modifying antirheumatic drugs, according to the results of a study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

18 Jun 2010

VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 possesses anti-inflammatory properties and effectively reduced the symptoms of arthritis in experimental models.

17 Jun 2010

Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR

ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).

17 Jun 2010

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

This bacterium, Escherichia coli K1, is the most common cause of meningitis in premature infants and the second most common cause of the disease in newborns. "The ineffectiveness of antibiotics in treating newborns with meningitis and the emergence of antibiotic-resistant strains of bacteria require new strategies," explains Nemani V. Prasadarao, PhD, associate professor of infectious disease at Childrens Hospital Los Angeles.

17 Jun 2010

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

A team of researchers at Childrens Hospital Los Angeles (CHLA), along with colleagues from the Keck School of Medicine of the University of Southern California and the Universite Auvergne, France, have discovered an important role for a small, naturally occurring protein called interleukin-10 (IL-10) in removing bacteria from the blood of infected mice and reversing damage to the brain.

11 Jun 2010

Research findings open door to development of new therapies for lymphomas, leukemias

Scripps Research Institute scientists have discovered a new way to target and destroy a type of cancerous cell. The findings may lead to the development of new therapies to treat lymphomas, leukemias, and related cancers.

8 Jun 2010

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

In a surprising discovery that someday may lead to new treatments for many inflammatory diseases, University of Utah scientists found that a hormone involved in iron metabolism can save mice from deadly acute inflammation.

8 Jun 2010

Small molecule ramps up interferon production in host cells, launching potent immune response

Many disease-causing microbes carry pumps that expel antibiotics, making the bugs hard to kill with standard drugs. Ironically, these same pumps could be the bugs' Achilles heel.

28 May 2010

PET scanning provides great insight into immune response

A commonly used probe for Positron Emission Tomography scanning and a new probe developed by researchers at UCLA reveal different functions in diverse cells of the immune system, providing a non-invasive and much clearer picture of an immune response in action.

19 May 2010

Scientists discover prothymosin-alpha protein to control HIV and other infections

Scientists at Duke University Medical School and Mount Sinai School of Medicine have found a new role for a host protein that provides further insight into how CD8+ T cells work to control HIV and other infections. Study authors say the finding may yield new strategies for prevention or treatment.

18 May 2010

Potential new drug therapies for treatment of tuberculosis

Tuberculosis (TB) has been present in humans since ancient times. The origins of the disease date back to the first domestication of cattle, and skeletal remains show prehistoric humans (4,000 B.C.) had TB. Although relatively rare in the United States, it is the single leading bacterial cause of death worldwide. Approximately 8 million people are infected each year and 2 million people die from TB.

11 May 2010

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest Laboratories, Inc. and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations.

10 May 2010

Encouraging B. anthracis to unwittingly unmask itself will help eradicate the pathogen

Anthrax-causing bacteria can be engineered to shed their invisibility cloaks, making it easier for the immune system to eradicate it, according to a new study published in Microbiology. The work could lead to new measures to treat anthrax infection in the event of a biological warfare attack.

7 May 2010

Scientists catch new mediators to develop novel treatments for diseases linked to inflammatory processes

Scientists at the University of Pittsburgh School of Medicine went on a molecular fishing trip and netted a catch of new mediators that not only can explain how omega-3 fatty acids reduce inflammation, but also hint at novel treatments for a host of diseases linked to inflammatory processes. Their findings were published today in the online version of Nature Chemical Biology.

6 May 2010

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

3 May 2010

MorphoSys AG reports Q1 results for 2010

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) today announced its financial results for the three months ending March 31, 2010 according to International Financial Reporting Standards (IFRS).

27 Apr 2010

Macrophage News and Research

Further Reading

New research shows cellular changes in fat tissue lead to type 2 diabetes

Multicolor quantum dots can distinguish Reed-Sternberg cells, article shows

Scientist at Children Hospital Los Angeles receives NIH grant to research on meningitis

START proteins could help treat cholesterol build-up in arteries: Report

Expression of BCRP in RA patients may indicate higher disease activity, predict resistance to DMARDs

VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR

Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

Research findings open door to development of new therapies for lymphomas, leukemias

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

Small molecule ramps up interferon production in host cells, launching potent immune response

PET scanning provides great insight into immune response

Scientists discover prothymosin-alpha protein to control HIV and other infections

Potential new drug therapies for treatment of tuberculosis

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Encouraging B. anthracis to unwittingly unmask itself will help eradicate the pathogen

Scientists catch new mediators to develop novel treatments for diseases linked to inflammatory processes

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

MorphoSys AG reports Q1 results for 2010

Microbiology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News